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Abstract High-grade osteosarcoma has a poor prognosis
with an overall survival rate of about 60 percent. The
recently closed European and American Osteosarcoma
Study Group (EURAMOS)-1 trial investigates the efﬁcacy
of adjuvant chemotherapy with or without interferon-a.I ti s
however unknown whether the interferon-signaling path-
ways in immune cells of osteosarcoma patients are func-
tional. We studied the molecular and functional effects of
interferon treatment on peripheral blood lymphocytes and
monocytes of osteosarcoma patients, both in vivo and ex
vivo. In contrast to other tumor types, in osteosarcoma,
interferon signaling as determined by the phosphorylation
of signal transducer and activator of transcription (STAT)1
at residue 701 was intact in immune cell subsets of 33
osteosarcoma patients as compared to 19 healthy controls.
Also, cytolytic activity of interferon-a stimulated natural
killer cells against allogeneic (n = 7 patients) and autolo-
gous target cells (n = 3 patients) was not impaired. Lon-
gitudinal monitoring of three osteosarcoma patients on
interferon-a monotherapy revealed a relative increase in
the CD16-positive subpopulation of monocytes during
treatment. Since interferon signaling is intact in immune
cells of osteosarcoma patients, there is a potential for
indirect immunological effects of interferon-a treatment in
osteosarcoma.
Keywords Osteosarcoma  Tumor immunology 
Interferon-a  NK cell
Abbreviations
APC Allophycocyanin
E:T Effector:target
EURAMOS European and American Osteosarcoma
Study Group
FCS Fetal calf serum
FITC Fluorescein isothiocyanate
HD Healthy donor
IFN Interferon
JAK Janus Kinase
IL Interleukin
mDC Myeloid dendritic cell
NK Natural killer
PBMC Peripheral blood mononuclear cells
pDC Plasmacytoid dendritic cell
PE Phycoerythrin
PerCP Peridinin chlorophyll protein
P/S Penicillin/streptomycin
STAT Signal transducer and activator of
transcription
Introduction
High-grade osteosarcoma is a primary malignant bone
tumor with an overall survival rate of about sixty percent
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DOI 10.1007/s00262-012-1232-6[1]. Intensiﬁcation of chemotherapeutic treatment has not
led to improved outcome, and other therapeutic modalities
are currently under investigation [2]. The recently closed
for accrual European and American Osteosarcoma Study
Group (EURAMOS)-1 trial investigates whether mainte-
nance treatment with interferon(IFN)-a-2b after standard
chemotherapy for osteosarcoma patients who have a good
response to preoperative chemotherapy (i.e.,[90%
necrotic tumor tissue) is effective [3, 4]. IFN-a has proven
anti-tumor effect in several tumor types, such as hairy cell
leukemia and renal cell cancer, and has been used in
osteosarcoma patients as adjuvant treatment in Scandinavia
since the 1970s [5–7].
The anti-proliferative effect of IFN-a on osteosarcoma
cells has been shown in vitro and in a xenograft model in
nude mice [8, 9]. Also, expression of IFN receptors on
human osteosarcoma cells is associated with a better
prognosis [10]. However, IFN-a can also exert indirect
anti-tumor activity; for example, through immunostimu-
latory effects. The type I IFNs (IFN-a and -b) binds to
the IFN type I receptor consisting of the two subunits
IFNAR1 and IFNAR2, which is expressed by immune
cells such as natural killer (NK) cells and monocytes
[11, 12]. Indirect anti-tumor effects of type I IFNs were
essential for the clearance of immunogenic sarcomas in
IFNAR1 deﬁcient mice, since it was dependent on the
expression of IFNAR1 on hematopoietic host cells and
not on tumor cells [13]. Whether similar indirect anti-
tumor effects also occur in the treatment for human
osteosarcoma with type I IFNs is unknown. The binding
of type I and type II (IFN-c) IFNs to their respective
receptors results in the activation of Janus Kinase (JAK),
subsequent phosphorylation of signal transducer and
activator of transcription (STAT) and ﬁnally transcription
of target genes. Phosphorylation of STAT1 at tyrosine
residue 701 occurs rapidly following receptor–ligand
interaction and is critical for both type I and type II IFN
signaling [14]. IFN signaling as determined by STAT1
phosphorylation was impaired in lymphocytes of patients
suffering from breast cancer, melanoma, and gastroin-
testinal cancer [15–18]. Impaired IFN signaling may be
rescued at the level of JAK-1 induced STAT1 phos-
phorylation; for example, by interleukin (IL)-12 pre-
treatment, as was shown in a murine melanoma model
[19].
Here, we addressed the molecular and functional
effects of IFN treatment on immune cell subsets of
osteosarcoma patients, both in vivo and ex vivo. To
interpret the future results of the IFN-a treatment arm of
the EURAMOS-1 trial, it is essential to know whether
IFN-signaling pathways in immune cells of osteosarcoma
patients are intact.
Patients and methods
Patients
Peripheral blood mononuclear cells (PBMCs) of 33 newly
diagnosed osteosarcoma patients and 19 healthy controls
were available for ﬂow cytometric evaluation of IFN-
induced phosphorylation of STAT1 (Table 1). PBMCs of 7
patients and 7 controls were available for cytolytic exper-
iments. From three osteosarcoma patients treated with
IFN-a monotherapy following the completion of adjuvant
chemotherapy, PBMCs were collected at diagnosis (prior
to the start of chemotherapy), prior to the start of IFN-a
monotherapy and at one or two time points during the ﬁrst
few weeks of treatment with IFN-a (subcutaneous PegIn-
tron, 0.5 lg/kg/week for 4 weeks, then dose escalation to
1.0 lg/kg/week). PBMCs were obtained after written
informed consent, approved by the Institutional Review
Board. All samples were handled in a coded fashion.
Culture of cell lines and PBMCs
The cell line K562 (obtained from ATCC) and PBMCs
were cultured in RPMI 1640 medium (Invitrogen, Carls-
bad, CA) with 10% fetal calf serum (FCS, Invitrogen) and
1% penicillin/streptomycin (P/S, Invitrogen). PBMCs were
isolated by Ficoll density gradient centrifugation and stored
in liquid nitrogen. After thawing, cells were allowed to
recover overnight, except when used for ﬂow cytometric
evaluation of dendritic cell (DC) activation, in which case,
Table 1 Clinicopathological details of osteosarcoma patients and
healthy controls included
Osteosarcoma Healthy
controls
n 33 19
Male 18 (54.5%) 12 (63.2%)
Age median (range) 16 (6–56) 17 (8–45)
Location primary tumor
Distal femur 19 (57.6%)
Prox tibia 6 (18.2%)
Prox humerus 5 (15.2%)
Other long bone 3 (9.1%)
Histological subtype
Conventional 29 (87.9%)
Osteoblastic 24
Chondroblastic 3
Unusual 2
Telangiectatic 4 (12.1%)
High-grade surface 1 (3.0%)
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123cells were analyzed immediately. For cytolytic assays, cells
were cultured overnight with or without 100 IU/mL IFN-a
(Roche, Basel, Switzerland). Prior dose-ﬁnding pilot
experiments determined this dose to result in good cell
viability and reproducible NK cell activation (data not
shown). The primary cell culture L2635 was established
from a pre-treatment biopsy of osteosarcoma patient 398 as
described previously and maintained in RPMI 1640 with
20% FCS and 1% P/S [20].
Flow cytometric evaluation of IFN-induced
phosphorylation of STAT1
Cells were stained with surface staining antibodies in stain-
ing buffer (PBS with 0.05% bovine serum albumin without
sodium azide) for 30 min at 37C. Surface staining anti-
bodies used for natural killer (NK) and T-cell subsets were
ﬂuorescein isothiocyanate (FITC)-conjugated anti-CD3
(349201, BD, San Diego, CA) and allophycocyanin (APC)-
conjugated anti-CD56 (2474, IOtest/Immunotech, Mar-
seille, France). Antibodies used for monocyte and B cell
subsets were FITC-conjugated anti-CD20 and APC-conju-
gated anti-CD14 (345792 and 340436, BD). Cells were
stimulated with or without 1,000 IU/mL IFN-a or IFN-c for
15 min at 37C and ﬁxed in 4% paraformaldehyde, as pre-
viouslydescribedbyCritchley-Thorneetal.[15].Cellswere
permeabilizedusingice-coldPermBufferIII(BDPhosﬂow)
for 30 min and stained for 60 min on ice with phycoerythrin
(PE)-conjugated anti-STAT1 (directed against the N-termi-
nusofSTAT1todeterminetotalSTAT1levels,558537,BD)
andperidininchlorophyllprotein(PerCP)-Cy5.5-conjugated
anti-pY701-STAT1 (directed against phosphorylated
tyrosine residue 701 of STAT1 to determine the levels of
phosphorylated STAT1, 560113, BD). Isotype control anti-
bodies were used to correct for the background levels of
ﬂuorescence. All ﬂow cytometric analyses were done on a
FACScalibur with Cellquest software (both BD).
Flow cytometric evaluation of PBMC subsets
PBMC subsets were determined as follows: T cells were
CD3-PerCP-Cy5.5-positive (332771, BD), NK cells were
CD3-PerCP-Cy5.5-negative, and CD56-PE-positive
(R7251, Dako, Glostrup, Denmark), B-cells were CD20-
FITC-positive (345792, BD), and monocytes were CD14-
APC-positive (340436, BD). Myeloid dendritic cells
(mDCs) were CD3-, CD19-, and CD14-negative (all
PerCP-Cy5.5-conjugated, 332771, 332780, and 550787,
BD) and BDCA-1- and BDCA-2-positive (PE-conjugated,
Miltenyi Biotec, Bergisch Gladbach, Germany). Activation
status of mDCs was determined by evaluating mean ﬂuo-
rescence intensities of HLA-DR-APC (347403, BD) and
CD86-FITC (555657, BD). Plasmacytoid dendritic cells
(pDCs) were CD3-, CD19-, and CD14-negative and
BDCA-2-APC-positive (Miltenyi). Activation status of
pDCs was determined with anti-CD86-FITC and anti-
HLA-DR-PE (555657 and 347367, BD). Monocytes were
evaluated by CD14-PerCP-Cy5.5, CD16-PE (347617, BD),
HLA-DR-APC, and CD86-FITC.
Cytolytic assays
Four hour chromium release cytolytic assays were per-
formed as described earlier [20]. Brieﬂy, target cells were
incubated with 3.7 MBq sodium-51-chromate (PerkinEl-
mer, Wellesley, MA) for 1 h. Effector cells (with or without
overnight IFN-a stimulation) were incubated for 4 h with
2,500 target cells at eight effector:target (E:T) ratios in
triplicate. Using these conditions, cytolysis observed is
caused by NK cells, since antigen-speciﬁc T cells (which
are present at low frequencies if at all) are insufﬁciently
expanded. Therefore, the E:T ratios were corrected for the
percentage of NK cells of PBMCs as determined by ﬂow
cytometry. Maximum and spontaneous release was deter-
mined by incubating targets in 2N HCl or medium,
respectively. Supernatants were harvested and counted in a
gamma counter (Wallac, PerkinElmer). Speciﬁc lysis was
determined as: (experimental release-spontaneous release)/
(maximum release-spontaneous release) 9 100%.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
5.0 (LaJolla, CA). Two-sided P values lower than 0.05
were determined to be signiﬁcant.
Results and discussion
Peripheral blood monocytes and lymphocytes
of osteosarcoma patients have intact
interferon-signaling ex vivo
Total STAT-1 levels were similar in peripheral blood
subsets of osteosarcoma patients and healthy controls. To
determine whether the IFN-signaling pathway was intact,
we assessed STAT1 phosphorylation in IFN-stimulated
immune cells of controls and patients. Basal levels of
phospho-STAT1 were slightly lower in NK cells of oste-
osarcoma patients at diagnosis (n = 33) than in NK cells of
healthy controls (n = 19; Fig. 1a), similar to what has been
described for melanoma [21]. However, in contrast to what
has been reported for melanoma, breast cancer, and gas-
trointestinal cancer, IFN signaling was intact in immune
cells of osteosarcoma patients, as determined by a 15 min
ex vivo stimulus with 1,000 IU/mL IFN-a or IFN-c (results
Cancer Immunol Immunother (2012) 61:941–947 943
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Responses were similar in almost all PBMC subsets for
patients and controls, except for a hyperphosphorylation
of STAT1 in B- and NK cells of osteosarcoma patients in
response to IFN-a (Fig. 1b). The functional response of
NK cells of osteosarcoma patients and healthy controls to
IFN-a was similar, as both responded to overnight IFN-a
culture with increased cytolytic capacity toward the NK
cell target K562 (Fig. 1c). There was possibly some, but
not statistically signiﬁcant trend for correlation between
phosphorylated STAT1 in NK cells and percentage of
speciﬁc lysis of K562 (Fig. 1d, P value 0.06, Spearman r
0.52).
We previously showed higher cytolytic capacity of
IL-15-activated NK cells of osteosarcoma patients than of
healthy donors [20]. The binding of IL-15 and IFN-a to
their respective receptors has the association of JAK1 with
the receptors in common. Together with Tyk2, this results
in phosphorylation of STAT1 in case of IFN-a-signaling
and together with JAK3 in phosphorylation of STAT3 and
STAT5 in case of IL-15 signaling. The hyperphosphory-
lation of STAT1 in response to IFN-a and the earlier
reported increased cytolytic capacity in response to IL-15
in NK cells of osteosarcoma patients as compared to
healthy donors could be due to increased functionality
of the common upstream signaling molecule JAK1.
A B
C D
Fig. 1 PBMCs of osteosarcoma patients are normally responsive to
IFN-a. a Flow cytometric evaluation of basal levels of phosphorylated
STAT1 in immune cell subsets shows slightly lower levels of
phosphorylated STAT1 in NK cells of osteosarcoma patients at
diagnosis (n = 33) as compared to healthy donors (n = 19). b Fol-
lowing an in vitro stimulus with 1,000 IU/mL IFN-a, hyperphosph-
orylation of B and NK cells of osteosarcoma patients was observed.
For both a and b, error bars denote standard error of the mean;
student’s t-test P value\0.05 noted as *;\0.01 = **. c Lysis of the
allogeneic NK cell target K562 by PBMCs of healthy donors (HD)
and osteosarcoma patients (OS) increased signiﬁcantly following
overnight culture in 100 IU/mL IFN-a (IFN-a ?). Effector to target
(E:T) ratio was corrected for percentage of NK cells. Lysis was
similar by healthy donor and osteosarcoma patient derived cells.
Wilcoxon signed ranked test; P value\0.05 noted as *. d Following
overnight culture of PBMCs in IFN-a, percentage-speciﬁc lysis
correlated with fold change in pSTAT1 in NK cells (P value 0.06,
Spearman r 0.52)
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induced STAT phosphorylation [19]. However, levels of
IL-12(p70) were similar in plasma of patients and controls,
and IL-12(p70) levels did not correlate with IFN-a induced
STAT1 phosphorylation (data not shown). Whether
increased STAT1 phosphorylation in NK cells of osteo-
sarcoma patients is related to differential expression or
activity of JAK1 remains to be investigated.
Phenotypic and functional analysis of PBMCs
of osteosarcoma patients on IFN-a monotherapy
In three osteosarcoma patients who received IFN-a
monotherapy following chemotherapeutic treatment
according to the EURAMOS-1 protocol, detailed ﬂow
cytometric phenotypic analysis of PBMCs was performed
during the ﬁrst few weeks of IFN-a monotherapy. In all
three patients, B cell numbers were very low (on average
3% of lymphocytes) at the end of chemotherapeutic treat-
ment and during IFN treatment returned to levels similar to
those at diagnosis, before start of chemotherapy (on aver-
age about 30% of lymphocytes or 500 cells/lL). No con-
sistent changes were seen in percentage or absolute number
of mDCs, pDCs, NK-, or T cells. The activation status of
monocytes, mDCs, or pDCs did not change during the ﬁrst
weeks of treatment, as measured by the expression of
CD86 and HLA class II.
In all three patients, a reduction in percentage of mono-
cytes was seen during the ﬁrst 2–8 weeks of IFN treatment.
However, the relative contribution of CD16? monocyte
subpopulation increased (Figs. 2a, b). CD16? monocytes
are considered ‘‘pro-inﬂammatory’’ because of the high
expression of tumor necrosis factor (TNF)-a and low
expression of IL-10 [22]. These pro-inﬂammatory
A B
C D
Fig. 2 Effect of in vivo IFN-a administration on monocytes and NK
cells. a Following in vivo treatment with IFN-a of three osteosarcoma
patients, the percentage of monocytes of PBMCs decreased. b The
relative percentage of CD16-positive monocytes increased. c NK cells
which had been exposed to IFN-a in vivo showed less phosphory-
lation of STAT1 in response to ex vivo IFN-a stimulation. d Cytolysis
of the autologous osteosarcoma target cell line L2635 by PBMCs of
patient 398 did not change signiﬁcantly during in vivo treatment with
IFN-a (solid lines). Following overnight culture in 100 IU/mL IFN-a,
lysis by PBMCs collected at all time points increased (dashed lines).
Effector to target (E:T) ratio was corrected for the percentage of NK
cells. Error bars denote standard error of the mean of experiment
performed in triplicate
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been described for ‘‘pro-inﬂammatory’’ M1 type macro-
phages. We have recently demonstrated the prognostic sig-
niﬁcance of inﬁltrating macrophages in osteosarcoma [23].
Further studies are needed to determine whether IFN-
induced phenotypic changes in peripheral blood monocytes
are associated with changes in intratumoral macrophage
number or phenotype, and whether this is associated with
altered expression of speciﬁc cytokines. However, this will
require IFNs to be administered earlier, before resection of
the primary tumor or relapses.
During in vivo treatment with IFN-a, total STAT1 levels
in monocytes, NK cells, and T cells increased, but the basal
levels of phosphorylated STAT1 did not change in any of
the leukocyte subsets (data not shown). NK- and T cells,
which had been exposed to IFN-a in vivo, showed less
induction of phosphorylation of STAT1 in response to ex
vivo IFN-a stimulation (NK cells shown in Fig. 2c). Nev-
ertheless, induction of cytolytic capacity against the NK
cell target K562 and the osteosarcoma culture L2635 fol-
lowing overnight IFN-a stimulation of PBMCs was unim-
paired, both against autologous and allogeneic targets
(example shown for PBMCs of patient 398 and its autol-
ogous target cells L2635 in Fig. 2d), indicating that in vivo
treatment with IFN-a has not rendered these cells func-
tionally unresponsive to an additional ex vivo IFN
stimulus.
The lack of induction of phosphorylated STAT1 during
in vivo IFN-a treatment was surprising. There are several
possible explanations. Phosphorylation of STAT1 is an
event that occurs rapidly following IFN stimulus. Perhaps,
STAT1 phosphorylation in vivo can be observed when
PBMCs are analyzed within a few hours of ﬁrst adminis-
tration of IFN. Further studies are needed if this is indeed
the case and if so, if this supposed the early activation of
the JAK/STAT pathway in immune cells results in sus-
tained activation of target genes and functional pathways.
An alternative explanation might be that the level of IFN-
induced activation of immune cells in vivo is dose-
dependent and limited by toxic and adverse effects in vivo
[24]. An additional in vitro stimulus was able to induce
STAT1 phosphorylation and resulted in increased cytolytic
NK cell activity, suggesting that in vivo IFN-a-induced
immune cell activation might have been incomplete. On
the other hand, it is still possible that the prolonged, rela-
tively low level of IFN-a exposure in vivo on PBMCs does
result in sustained anti-tumor immune effects; for example,
through the observed changes in monocytes.
Concluding remarks
Treatment for osteosarcoma patients with the anti-prolif-
erative and immunomodulatory agent IFN-a could have
direct anti-tumor and/or indirect immune-mediated effects.
Here, we show IFN signaling to be intact in PBMCs of
osteosarcoma patients, as determined by the phosphoryla-
tion of STAT1 and increased NK cell-mediated cytolysis in
response to ex vivo IFN. Some of the experiments were
performed on small sample numbers, but since results were
consistent throughout, we believe the results to be valid in
determining responsiveness of immune cells of osteosar-
coma patients to IFN-a. Although the efﬁcacy of IFN-a
treatment in osteosarcoma will be assessed in the EURA-
MOS-1 trial, our data indicate that in contrast to some other
tumor types, immune cells of osteosarcoma patients have
retained IFN-responsiveness. Further clinical studies are
needed to establish the extent and efﬁcacy of indirect
immunotherapeutic effects of IFN-a treatment in osteo-
sarcoma patients.
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